Literature DB >> 28887716

Inhibitory effect and molecular mechanism of mesenchymal stem cells on NSCLC cells.

Mengwu Pan1, Lingling Hou2, Jingsi Zhang1, Diandian Zhao1, Jilei Hua1, Ziling Wang1, Jinsheng He1, Hong Jiang1, Honggang Hu1, Lishu Zhang1.   

Abstract

Non-small-cell lung cancer (NSCLC) is still the main threat of cancer-associated death. Current treatment of NSCLC has limited effectiveness, and unfortunately, the prognosis of NSCLC remains poor. Therefore, a novel strategy for cancer therapy is urgently needed. Stem cell therapy has significant potential for cancer treatment. Mesenchymal stem cells (MSCs) with capacity for self-renewal and differentiation into various cells types exhibit the feature of homing to tumor site and immunosuppression, have been explored as a new treatment for various cancers. Studies revealed that the broad repertoire of trophic factors secreted by MSCs extensively involved in the interplay between MSCs and tumor cells. In this study, we confirmed that MSCs do have the paracrine effect on proliferation and migration of NSCLC cells (A549, NCI-H460, and SK-MES-1). Co-culture system and conditioned medium experiments results showed that soluble factors secreted by MSCs inhibited the proliferation of NSCLC cells in vitro. The scratch assay showed that conditioned medium of MSCs could suppress the migration of NSCLC cells in vitro. Western blot results showed that the expression of proteins relevant to cell proliferation, anti-apoptosis, and migration was remarkably decreased via MAPK/eIF4E signaling pathway. We speculated that soluble factors secreted by MSCs might be responsible for inhibitory mechanism of NSCLC cells. By Human Gene Expression Microarray Assay and recombinant Vascular Endothelial Growth Factor 165 (VEGF165) neutralizing experiment, we verified that VEGF might be responsible for the down-regulation of proteins related to cell proliferation, anti-apoptosis, and migration by suppressing translation initiation factor eIF4E via MAPK signaling pathway. Taken together, our study demonstrated that a possible trophic factor secreted by MSCs could manipulate translation initiation of NSCLC cells via MAPK signaling pathway, and significantly affect the fate of tumor cells, which will be a new strategy for cancer therapy.

Entities:  

Keywords:  Inhibition; MAPK; MSCs; Mechanism; NSCLC

Mesh:

Year:  2017        PMID: 28887716     DOI: 10.1007/s11010-017-3174-y

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  55 in total

1.  Adipose tissue-derived mesenchymal stem cells cultured at high density express IFN-β and suppress the growth of MCF-7 human breast cancer cells.

Authors:  Hoon Ryu; Ji-Eun Oh; Ki-Jong Rhee; Soon Koo Baik; Jiye Kim; Seong Joon Kang; Joon Hyung Sohn; Eunhee Choi; Ha Cheol Shin; Yong Man Kim; Hyun Soo Kim; Keum Seok Bae; Young Woo Eom
Journal:  Cancer Lett       Date:  2014-07-10       Impact factor: 8.679

2.  Human mesenchymal stem cells play a dual role on tumor cell growth in vitro and in vivo.

Authors:  Lin Li Hui Tian; Weiming Yue; Feng Zhu; Shuhai Li; Wenjun Li
Journal:  J Cell Physiol       Date:  2011-07       Impact factor: 6.384

Review 3.  Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis.

Authors:  Robert S Kerbel; Eric Guerin; Giulio Francia; Ping Xu; Christina R Lee; John M L Ebos; Shan Man
Journal:  Breast       Date:  2013-08       Impact factor: 4.380

Review 4.  Mesenchymal stem cells as therapeutics and vehicles for gene and drug delivery.

Authors:  Christopher D Porada; Graça Almeida-Porada
Journal:  Adv Drug Deliv Rev       Date:  2010-09-07       Impact factor: 15.470

5.  Phosphorylation of the cap-binding protein eukaryotic translation initiation factor 4E by protein kinase Mnk1 in vivo.

Authors:  A J Waskiewicz; J C Johnson; B Penn; M Mahalingam; S R Kimball; J A Cooper
Journal:  Mol Cell Biol       Date:  1999-03       Impact factor: 4.272

6.  Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use.

Authors:  H M Lazarus; S E Haynesworth; S L Gerson; N S Rosenthal; A I Caplan
Journal:  Bone Marrow Transplant       Date:  1995-10       Impact factor: 5.483

7.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.

Authors:  John M L Ebos; Christina R Lee; William Cruz-Munoz; Georg A Bjarnason; James G Christensen; Robert S Kerbel
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743

8.  Exosomes derived from mesenchymal stem cells suppress angiogenesis by down-regulating VEGF expression in breast cancer cells.

Authors:  Jong-Kuen Lee; Sae-Ra Park; Bong-Kwang Jung; Yoon-Kyung Jeon; Yeong-Shin Lee; Min-Kyoung Kim; Yong-Goo Kim; Ji-Young Jang; Chul-Woo Kim
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

Review 9.  VEGFA and tumour angiogenesis.

Authors:  L Claesson-Welsh; M Welsh
Journal:  J Intern Med       Date:  2013-02       Impact factor: 8.989

Review 10.  The importance of the PI3K/AKT/MTOR pathway in the progression of ovarian cancer.

Authors:  Zachary C Dobbin; Charles N Landen
Journal:  Int J Mol Sci       Date:  2013-04-15       Impact factor: 5.923

View more
  2 in total

1.  Extracellular vesicles secreted by hypoxia pre-challenged mesenchymal stem cells promote non-small cell lung cancer cell growth and mobility as well as macrophage M2 polarization via miR-21-5p delivery.

Authors:  Weihua Ren; Jianfeng Hou; Chenguang Yang; Hanjun Wang; Shuangting Wu; Yabin Wu; Xingpeng Zhao; Chao Lu
Journal:  J Exp Clin Cancer Res       Date:  2019-02-08

Review 2.  Comparative Efficacy of Chinese Herbal Injections Combined with Paclitaxel Plus Cisplatin for Non-Small-Cell Lung Cancer: A Multidimensional Bayesian Network Meta-Analysis.

Authors:  Mengwei Ni; Haojia Wang; Miaomiao Wang; Wei Zhou; Jiarui Wu; Bin Sun; Qianqian Zhang; Xiaotian Fan; Dan Zhang; Zhiwei Jing; Jingyuan Zhang; Xinkui Liu; Shuyu Liu; Ziqi Meng; Siyu Guo; Shanshan Jia; Xiaomeng Zhang; Xiaoguang Sheng
Journal:  Evid Based Complement Alternat Med       Date:  2020-10-28       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.